Upstream Bio financials
$5.27+1.54%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $2.9M | $2.4M |
| Gross profit | $2.9M | $2.4M |
| Gross margin | 100.0% | 100.0% |
| Operating income | -$160.4M | -$77.8M |
| Net income | -$143.4M | -$76.4M |
| Net margin | −5026.0% | −3223.4% |
| Diluted EPS | $-2.66 | $-5.58 |
| EBITDA | -$160.2M | -$77.7M |
| Operating cash flow | -$133.3M | -$59.2M |
| Free cash flow | -$133.4M | -$59.7M |
| Diluted shares | 53.9M | 13.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $101.6M | $325.9M |
| Short-term investments | $239.9M | $144.6M |
| Total debt | $0.00 | $0.00 |
| Total assets | $353.8M | $481.7M |
| Total liabilities | $14.0M | $11.9M |
| Shareholders' equity | $339.8M | $469.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology